Insights On Outsourced Drug Development

  1. Analyzing Biological Drug Effects In 3D 10/24/2025

    Explore how 3D tumor microtissues paired with fluorescence-based assays offer scalable, high-sensitivity drug testing to deliver stronger signals and reproducible results compared to monolayer cultures.

  2. Leveraging Optimized Transient Expression For Material Generation And Early Stage Insight 7/23/2024

    By using an optimized transient transfection platform, drug developers can accelerate their characterization and early development activities, facilitating continuity for a drug's scale-up.

  3. Building Better Degraders: Targeted Protein Degradation Partners 3/1/2024

    Learn from industry experts about the latest advances in chemical building blocks for protein degradation, including warheads, linkers, and ligands, and their role in constructing superior degrades.

  4. Preclinical Evaluation Of New Antifibrotics In NASH-Induced Fibrosis Models 6/10/2025

    Accelerate the development of antifibrotic therapies through our clinically relevant models, deep scientific expertise, and proven preclinical capabilities in this area of unmet medical need.

  5. Analysis Of Drug-Excipient Incompatibility In Discovery And Formulation Development 3/7/2024

    We analyze drug-excipient incompatibility using a microcalorimeter system equipped with a multi-sample cell capable of simultaneously measuring highly sensitive heat flow data from up to three samples.

  6. Early Development Considerations For Late-Stage NCE Success – Part One 12/8/2023

    Navigating NCE development can be daunting. Learn about the importance of assessing and mitigating risk at every stage of development and ensure that your NCE has the maximum potential for success.

  7. Is Industry Ready To Take A Bite Out Of Obesity? 7/15/2024

    What are the clinical, economic, and policy considerations for a class of drugs offering a promising treatment for obesity, and how is the industry adapting to meet demand?

  8. The Art And Science Of Topical Formulations 7/3/2025

    Chief Scientific Officer Jon Lenn discusses the balance of art and science in topical formulation development, emphasizing advanced skin models for optimized delivery, activity, and product stability.

  9. A New Framework For Identifying Nitrosamine Risks And Derisking Products 6/18/2024

    Examine a new methodology that holds significant promise for identifying APIs at risk for NDSRI formation, enabling manufacturers to prioritize risk mitigation strategies and ensure compliance.

  10. Fast And Efficient Processing Of ELISA Assays 10/24/2025

    Explore how a streamlined ELISA workflow using automated washing and reading tools enabled accurate detection of hepatitis B markers with no false results.